Cargando…
A diagnostic challenge of seromucinous borderline tumor: A case report
INTRODUCTION: Magnetic resonance (MR) relaxometry provides a noninvasive predictive tool to discriminate between benign ovarian endometrioma (OE) and endometriosis-associated ovarian cancer (EAOC). Transverse relaxation rate R2 value was determined using a single-voxel, multi-echo MR sequence (HISTO...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709009/ https://www.ncbi.nlm.nih.gov/pubmed/31145284 http://dx.doi.org/10.1097/MD.0000000000015707 |
_version_ | 1783446109512794112 |
---|---|
author | Liu, Tingting Sumida, Daichi Wada, Takuya Maehana, Tomoka Yamawaki, Aika Sugimoto, Sumire Kawahara, Naoki Yoshimoto, Chiharu Kobayashi, Hiroshi |
author_facet | Liu, Tingting Sumida, Daichi Wada, Takuya Maehana, Tomoka Yamawaki, Aika Sugimoto, Sumire Kawahara, Naoki Yoshimoto, Chiharu Kobayashi, Hiroshi |
author_sort | Liu, Tingting |
collection | PubMed |
description | INTRODUCTION: Magnetic resonance (MR) relaxometry provides a noninvasive predictive tool to discriminate between benign ovarian endometrioma (OE) and endometriosis-associated ovarian cancer (EAOC). Transverse relaxation rate R2 value was determined using a single-voxel, multi-echo MR sequence (HISTO) by a 3T-MR system. R2 with cutoff value of 12.1 s(−1) was established to discriminate between benign and malignant tumors. PATIENT CONCERNS: We present a case of a 39-year-old woman who was initially thought to be malignant transformation of endometriosis by diagnostic MR imaging of the vascularized solid components. DIAGNOSIS: A R2 value of 42.62 s(−1) on MR relaxometry demonstrated that this case is non-malignant. INTERVENTIONS: To confirm the diagnose, left salpingo-oophorectomy by laparoscopic surgery was performed. OUTCOMES: Histopathological results revealed seromucinous borderline tumor (SMBT). Our experience suggests that preoperative MR relaxometry may be useful for discriminating “borderline (SMBT)” from “malignancy (EAOC).” Furthermore, immunohistochemical studies of this case demonstrated ovarian SMBT cells were positive for estrogen receptor, progesterone receptor, and hepatocyte nuclear factor-1beta. A similar expression pattern was also observed in patients with benign OE. LESSONS: In many respects, SMBT characteristics differ from those of EAOC but resemble those of benign OE. MR relaxometry unveils a new clinical approach as an adjunctive modality for discriminating SMBT from EAOC. |
format | Online Article Text |
id | pubmed-6709009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-67090092019-10-01 A diagnostic challenge of seromucinous borderline tumor: A case report Liu, Tingting Sumida, Daichi Wada, Takuya Maehana, Tomoka Yamawaki, Aika Sugimoto, Sumire Kawahara, Naoki Yoshimoto, Chiharu Kobayashi, Hiroshi Medicine (Baltimore) Research Article INTRODUCTION: Magnetic resonance (MR) relaxometry provides a noninvasive predictive tool to discriminate between benign ovarian endometrioma (OE) and endometriosis-associated ovarian cancer (EAOC). Transverse relaxation rate R2 value was determined using a single-voxel, multi-echo MR sequence (HISTO) by a 3T-MR system. R2 with cutoff value of 12.1 s(−1) was established to discriminate between benign and malignant tumors. PATIENT CONCERNS: We present a case of a 39-year-old woman who was initially thought to be malignant transformation of endometriosis by diagnostic MR imaging of the vascularized solid components. DIAGNOSIS: A R2 value of 42.62 s(−1) on MR relaxometry demonstrated that this case is non-malignant. INTERVENTIONS: To confirm the diagnose, left salpingo-oophorectomy by laparoscopic surgery was performed. OUTCOMES: Histopathological results revealed seromucinous borderline tumor (SMBT). Our experience suggests that preoperative MR relaxometry may be useful for discriminating “borderline (SMBT)” from “malignancy (EAOC).” Furthermore, immunohistochemical studies of this case demonstrated ovarian SMBT cells were positive for estrogen receptor, progesterone receptor, and hepatocyte nuclear factor-1beta. A similar expression pattern was also observed in patients with benign OE. LESSONS: In many respects, SMBT characteristics differ from those of EAOC but resemble those of benign OE. MR relaxometry unveils a new clinical approach as an adjunctive modality for discriminating SMBT from EAOC. Wolters Kluwer Health 2019-05-31 /pmc/articles/PMC6709009/ /pubmed/31145284 http://dx.doi.org/10.1097/MD.0000000000015707 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Liu, Tingting Sumida, Daichi Wada, Takuya Maehana, Tomoka Yamawaki, Aika Sugimoto, Sumire Kawahara, Naoki Yoshimoto, Chiharu Kobayashi, Hiroshi A diagnostic challenge of seromucinous borderline tumor: A case report |
title | A diagnostic challenge of seromucinous borderline tumor: A case report |
title_full | A diagnostic challenge of seromucinous borderline tumor: A case report |
title_fullStr | A diagnostic challenge of seromucinous borderline tumor: A case report |
title_full_unstemmed | A diagnostic challenge of seromucinous borderline tumor: A case report |
title_short | A diagnostic challenge of seromucinous borderline tumor: A case report |
title_sort | diagnostic challenge of seromucinous borderline tumor: a case report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709009/ https://www.ncbi.nlm.nih.gov/pubmed/31145284 http://dx.doi.org/10.1097/MD.0000000000015707 |
work_keys_str_mv | AT liutingting adiagnosticchallengeofseromucinousborderlinetumoracasereport AT sumidadaichi adiagnosticchallengeofseromucinousborderlinetumoracasereport AT wadatakuya adiagnosticchallengeofseromucinousborderlinetumoracasereport AT maehanatomoka adiagnosticchallengeofseromucinousborderlinetumoracasereport AT yamawakiaika adiagnosticchallengeofseromucinousborderlinetumoracasereport AT sugimotosumire adiagnosticchallengeofseromucinousborderlinetumoracasereport AT kawaharanaoki adiagnosticchallengeofseromucinousborderlinetumoracasereport AT yoshimotochiharu adiagnosticchallengeofseromucinousborderlinetumoracasereport AT kobayashihiroshi adiagnosticchallengeofseromucinousborderlinetumoracasereport AT liutingting diagnosticchallengeofseromucinousborderlinetumoracasereport AT sumidadaichi diagnosticchallengeofseromucinousborderlinetumoracasereport AT wadatakuya diagnosticchallengeofseromucinousborderlinetumoracasereport AT maehanatomoka diagnosticchallengeofseromucinousborderlinetumoracasereport AT yamawakiaika diagnosticchallengeofseromucinousborderlinetumoracasereport AT sugimotosumire diagnosticchallengeofseromucinousborderlinetumoracasereport AT kawaharanaoki diagnosticchallengeofseromucinousborderlinetumoracasereport AT yoshimotochiharu diagnosticchallengeofseromucinousborderlinetumoracasereport AT kobayashihiroshi diagnosticchallengeofseromucinousborderlinetumoracasereport |